H Rosner1, L Rubin, A Kestenbaum. 1. Department of Anesthesiology, New York Hospital, Cornell Medical Center, New York 10021, USA.
Abstract
OBJECTIVE: This is a report of a trial of the new antiepileptic agent gabapentin in patients with intractable neuropathic pain. DESIGN: A case series of patients with a diagnosis of neuropathic pain whose previous management was inadequate were given oral gabapentin in increasing doses and were followed for a minimum of 2 months, monitored for efficacy and side effects. SETTING: An outpatient pain management center located within a major university medical center. PATIENTS: Convenience sample of patients referred for management of intractable neuropathic pain. INTERVENTIONS: Simplification of existing pharmacologic management, addition of gabapentin, and attempted reduction of opiate analgesic doses. MAIN OUTCOME MEASURES: Patient self-reports and pain scores in successive office visits. RESULTS: Gabapentin provides analgesic activity for patients with neuropathic pain and has the advantage of a low side effect profile and drug toxicity.
OBJECTIVE: This is a report of a trial of the new antiepileptic agent gabapentin in patients with intractable neuropathic pain. DESIGN: A case series of patients with a diagnosis of neuropathic pain whose previous management was inadequate were given oral gabapentin in increasing doses and were followed for a minimum of 2 months, monitored for efficacy and side effects. SETTING: An outpatientpain management center located within a major university medical center. PATIENTS: Convenience sample of patients referred for management of intractable neuropathic pain. INTERVENTIONS: Simplification of existing pharmacologic management, addition of gabapentin, and attempted reduction of opiate analgesic doses. MAIN OUTCOME MEASURES: Patient self-reports and pain scores in successive office visits. RESULTS:Gabapentin provides analgesic activity for patients with neuropathic pain and has the advantage of a low side effect profile and drug toxicity.
Authors: Z D Luo; S R Chaplan; E S Higuera; L S Sorkin; K A Stauderman; M E Williams; T L Yaksh Journal: J Neurosci Date: 2001-03-15 Impact factor: 6.167